A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

Sponsor
Zheng Min
Study ID
NCT07348861
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Sacituzumab tirumotecan plus Iparomlimab — DRUG
    Sacituzumab tirumotecan 5mg/kg iv. drip,Q2W Iparomlimab and Tuvonralimab 3mg/kg iv.drip, Q2W

Study Details

This is a phase II, prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with iparomlimab and tuvonralimab as neoadjuvant therapy in patients with locally advanced cervical cancer

Key Dates

First listed
Jan 16, 2026
Start date
Feb 1, 2026
Status verified
Jan 2026
Primary completion
Jan 1, 2028
Completion
Jan 1, 2028

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sacituzumab tirumotecan plus Iparomlimab

Primary Outcome Measure

Rate of pathological complete response [ Time Frame: From enrollment to the end of treatment at 8 weeks ]

Central Contacts

Find similar trials

Nationwide
Cervical cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials

Related Studies